Vimy Pharmaceuticals Inc. raised $1.01M (Form D, Oct 2026)

Key facts

Filed 2026-10-13 · Form D filed with the SEC · Form D
As filed 2026-10-13 · Sold to date: $1.01M · Form D
As filed 2026-10-13 · Total offering: $1.01M · Form D
As filed 2026-10-13 · First sale: 2026-09-28 · Form D
As filed 2026-10-13 · Investors already in: 7 · Form D

What the filing says

Offered: $1,010,798. Sold: $1,010,798. Left to sell: nothing, all of it is sold. (filing)
Investors: 7 had already invested. (filing)
Date of first sale: September 28, 2026. (filing)
Types of securities: Equity. (filing)
Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
Securities that converted: the filing says “CAD converted to USD at the same rate” (filing)
Securities that converted: the filing says “The Issuer sold subscription receipts, which will be converted into shares of the Issuer without consideration upon the closing of the transaction.” (filing)
On the amounts offered and sold: the filing adds “The total offering amount was $1,432,200 in Canadian dollars. The U.S. dollar value above is based on the Federal Reserve exchange rate on September 28, 2026 of $1.4169 CAD per USD.” (filing)
On sales commissions and finders' fees: the filing adds “Consists of (i) $34,583 cash fee; (ii) President's List purchasers: $2,757 cash fee and $2,757 in options, each 3% of such sales; (iii) other purchasers: $55,134 cash fee and $55,134 in options, each 6% of such sales. CAD converted to USD at the same rate” (filing)
On the business combination question: the filing adds “The Issuer sold subscription receipts, which will be converted into shares of the Issuer without consideration upon the closing of the transaction.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Vimy Pharmaceuticals Inc. See pricing

Pharmaceuticals · by week

Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $1.01M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Vimy Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Vimy Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vimy Pharmaceuticals Inc. covers

The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28

A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Vimy Pharmaceuticals Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Vimy Pharmaceuticals Inc. — $1.01M Form D filing, October 2026